Skip to main content

Table 1 Total NADC (lung, liver, and head and neck) patient characteristics, 2010-2014a

From: Changing Patterns of lung, liver, and head and neck non-AIDS-defining cancers relative to HIV status in Tanzania between 2002-2014

  All NADCs
(N = 1127)
N (%)
Lung
(N = 101)
N (%)
Liver
(N = 151)
N (%)
Oral cavity/Oropharynxb
(N = 421)
N (%)
Nasal cavity/paranasal sinusesc
(N = 230)
N (%)
Hypopharynx/larynx/trachead
(N = 224)
N (%)
Female 410 (36.4%) 51 (50.5%) 63 (41.7%) 159 (37.8%) 98 (42.6%) 39 (17.4%)
Mean Age ± SD 54.3 ± 15.8 58.6 ± 13.8 47.1 ± 15.6 56.6 ± 15.2 47.9 ± 16.6 59.3 ± 13.4
Residence in Dar es Salaam 448 (39.8%) 53 (52.5%) 70 (46.4%) 140 (33.3%) 91 (39.6%) 95 (42.4%)
Smoking Status
 Previous 404 (35.9%) 33 (32.7%) 27 (17.9%) 170 (40.4%) 52 (22.6%) 122 (54.5%)
 Current 25 (2.2%) 2 (2.0%) 2 (1.3%) 12 (2.9%) 1 (0.4%) 8 (3.6%)
 Never 477 (42.3%) 39 (38.6%) 71 (47.0%) 169 (40.1%) 125 (54.4%) 73 (32.6%)
Alcohol use
 Previous 411 (36.5%) 30 (29.7%) 39 (25.8%) 182 (43.2%) 52 (22.6%) 108 (48.2%)
 Current 54 (4.8%) 5 (5.0%) 5 (3.3%) 19 (4.5%) 11 (4.8%) 14 (6.3%)
 Never 399 (35.4%) 31 (30.7%) 59 (39.1%) 143 (34.0%) 107 (46.5%) 59 (26.3%)
Tuberculosis 94 (8.3%) 26 (25.7%) 4 (8.0%) 32 (22.4%) 17 (22.4%) 15 (19.7%)
Co-morbiditiesf
 Mean count ± SD 0.46 ± 0.76 0.97 ± 0.98 0.77 + 0.93 0.37 ± 0.65 0.34 ± 0.67 0.34 ± 0.63
HIV-status
 Positive 81 (7.2%) 4 (4.0%) 11 (7.3%) 36 (8.6%) 22 (9.6%) 8 (3.6%)
 Negative 189 (16.8%) 26 (25.7%) 24 (16.0%) 87 (20.7%) 38 (16.5%) 14 (6.3%)
 Unknown 857 (76.0%) 71 (70.3%) 116 (76.8%) 298 (70.8%) 170 (73.9%) 202 (90.2%)
Advanced cancer stagee 655 (58.1%) 42 (41.6%) 49 (32.5%) 291 (98.0%) 135 (95.1%) 138 (85.7%)
Cancer Treatment Modality
 Radiotherapy 770 (68.3%) 32 (31.7%) 40 (29.0%) 332 (81.6%) 174 (80.9%) 192 (88.1%)
 Chemotherapy 574 (50.9%) 60 (59.4%) 87 (63.0%) 184 (45.3%) 128 (59.8%) 115 (52.5%)
 Both 414 (38.6%) 15 (14.9%) 25 (18.1%) 158 (38.7%) 112 (52.1%) 104 (47.3%)
Recurrence 41 (3.6%) 0 0 20 (4.8%) 18 (7.8%) 3 (1.3%)
Subsequent cancer diagnosis (at least one) 159 (14.1%) 34 (33.7%) 30 (19.9%) 37 (8.8%) 39 (17.0%) 19 (8.5%)
Recorded Death 149 (13.2%) 14 (13.9%) 33 (21.9%) 51 (12.1%) 27 (11.7%) 24 (10.7%)
  1. aTotals vary due to missing data
  2. bOral cavity/oropharynx cancers include oropharynx, parotid, tongue, oral cavity, soft/hard palate, lip, salivary gland, gingiva, intra-oral mandible, and tonsil according to WHO/IARC tumor classification
  3. cNasal cavity/paranasal sinuses cancers include maxilla, maxillary sinus, sinonasal, nasal, and nasopharynx according to WHO/IARC tumor classification
  4. dHypopharynx/larynx/trachea cancers include larynx, Hypopharynx, glottis, vallecula, pharynx, neck (non-skin), and submandibular according to WHO/IARC tumor classification
  5. eDefined as stages 3–4 and metastatic malignancies, % represents reported pathology department diagnosis
  6. fComorbidities include Comorbidities include malaria, pleural effusion, pneumonia, ascites, syphilis, liver cysts, oral thrush, oral ulcers, sinusitis, yellow fever, etc